Ludwig Christine, Wagner Ralf
Molecular Microbiology and Gene Therapy Unit, Institute of Medical Microbiology and Hygiene, University of Regensburg, 93053 Regensburg, Germany.
Curr Opin Biotechnol. 2007 Dec;18(6):537-45. doi: 10.1016/j.copbio.2007.10.013.
Virus-like particles (VLPs) are highly organised spheres that self-assemble from virus-derived structural antigens. These stable and versatile subviral particles possess excellent adjuvant properties capable of inducing innate and cognate immune responses. Commercialised VLP-based vaccines have been successful in protecting humans from hepatitis B virus (HBV) and human papillomavirus (HPV) infection and are currently explored for their potential to combat other infectious diseases and cancer. Much insight into VLP-mediated immune stimulation and optimised VLP design has been gained from human immunodeficiency virus (HIV)-derived VLPs presenting promising components of current AIDS vaccine approaches. Owing to their unique features, VLPs and virosomes, the in vitro-reconstituted VLP counterparts, have recently gained ground in the field of nanobiotechnology as organic templates for the development of new biomaterials.
病毒样颗粒（VLPs）是由病毒衍生的结构抗原自组装形成的高度有序的球体。这些稳定且通用的亚病毒颗粒具有出色的佐剂特性，能够诱导天然免疫和相关免疫反应。基于VLP的商业化疫苗已成功保护人类免受乙型肝炎病毒（HBV）和人乳头瘤病毒（HPV）感染，目前正在探索其对抗其他传染病和癌症的潜力。从呈现当前艾滋病疫苗方法中很有前景成分的人类免疫缺陷病毒（HIV）衍生的VLPs中，人们对VLP介导的免疫刺激和优化的VLP设计有了很多了解。由于其独特的特性，VLPs和体外重组的VLP对应物病毒体，最近在纳米生物技术领域作为开发新型生物材料的有机模板而受到青睐。
